Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Glycerine,Dextrans
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : OcuMension Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
OcuMension Acquires Alcon Eye Drops with 16.7% Equity, Strategic Partnership Begins
Details : OcuMension will acquire outright, Tears Natural Forte, Bion Tears, Alcaine, Fluorescite, and Cyclogyl, in the Chinese market and AR-15512, a novel topical drug candidate for dry eye.
Brand Name : Tears Naturale Forte
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 12, 2024
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Glycerine,Dextrans
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : OcuMension Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Dextrans
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tikomed's ILB® Restores Brain Energy Metabolism Following Severe Traumatic Brain Injury in the Rat
Details : The data from the rodent model studying severe traumatic brain injury (sTBI), showed that a single post-injury injection of ILB® has beneficial effects on the metabolic damages caused by sTBI.
Brand Name : ILB
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 14, 2020
Lead Product(s) : Dextrans
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?